Clinical trials: Progressive Multifocal Leukoencephalopathy
Progressive Multifocal Leukoencephalopathy
Natural History Study of Progressive Multifocal Leukoencephalopathy (PML)
Background: Progressive multifocal leukoencephalopathy (PML) is a severe viral infection of the brain. It is caused by JC virus.
- Trial name
- NCT01730131
- Where
- United States
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Progressive Multifocal Leucoencephalopathy (PML)
T-cell Therapy in Patients With PML
There is no approved standard treatment für progressive multifocal leukoencephalopathy (PML). The sponsor of the study is developing a new treatment.
- Trial name
- NCT06990087
- Testing
- Application of T-lymphocytes
- Where
- 7 sites in Germany
- Volunteers
- 23 people
- Sponsor
- Hannover Medical School
Multiple Sclerosis, Progressive Multifocal Leukoencephalopathy
Risk of Progressive Multifocal Leukoencephalopathy Among Patients With Multiple Sclerosis Exposed to Zeposia
This study will evaluate the risk of progressive multifocal leukoencephalopathy (PML), a rare brain infection caused by John Cunningham virus (JCV), among people with multiple sclerosis who have been treated with ozanimod.
- Trial name
- NCT07732907
- Testing
- Ozanimod
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Bristol-Myers Squibb
Progressive Multifocal Leukoencephalopathy
Intravenous Brincidofovir as an Antiviral for Treatment of Progressive Multifocal Leukoencephalopathy: A Pilot Study
Background: Progressive multifocal leukoencephalopathy (PML) is a rare and often fatal brain infection caused by the JC virus. The JC virus is common. More than half of adults have been exposed to it.
- Trial name
- NCT07511049
- Testing
- Brincidofovir
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Progressive Multifocal Leukoencephalopathy
Adoptive Cellular Immunotherapy for Progressive Multifocal Leukoencephalopathy With Ex Vivo Generated Polyomavirus-Specific T-Cells
Background: Progressive Multifocal Leukoencephalopathy (PML) is a brain infection in people with a weakened immune system. Researchers think polyoma virus specific T cells (PyVST) therapy can treat PML.
- Trial name
- NCT02694783
- Testing
- PyVST
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Progressive Multifocal Leukoencephalopathy, Multiple Sclerosis
Central Nervous System Uptake of Anti-CD8+ T Cell Minibodies in Multiple Sclerosis and Progressive Multifocal Leukoencephalopathy
Background: Multiple sclerosis (MS) and progressive multifocal leukoencephalopathy (PML) are disorders that affect the central nervous system (CNS). The CNS includes the brain, spinal cord, and optic nerves.
- Conditions
- Progressive Multifocal Leukoencephalopathy, Multiple Sclerosis, Other Neuroinflammatory Diseases With BBB Leakage
- Trial name
- NCT05849467
- Testing
- 89 Zr-Df-crefmirlimab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Progressive Multifocal Leukoencephalopathy, Immune Checkpoint Inhibitors
Observational Cohort Study of Chronic Viral Infection in the Central Nervous System
This research team intends to conduct a real-world cohort study of chronic CNS viral infections represented by PML, to evaluate whether administration of immune checkpoint inhibitors improves long-term outcomes in this patient…
- Trial name
- NCT07512518
- Testing
- Immune Checkpoint Inhibitors
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Peking Union Medical College Hospital
Leukoencephalopathy, Progressive Multifocal, HIV Infections
Early Intensification of Antiretroviral Therapy Including Enfuvirtide in HIV-1-Related Progressive Multifocal Leucoencephalopathy (ANRS125)
Progressive multifocal leucoencephalopathy (PML) is a rare infectious disease of the brain, provoked by the JC virus. It usually occurs in subjects with impaired immune system as during HIV infection.
- Trial name
- NCT00120367
- Testing
- Enfuvirtide, Tenofovir-Emtricitabine
- Where
- France
- Volunteers
- 30 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
Progressive Multifocal Leukoencephalopathy
Dynamics of T Cell Expression of Immune Checkpoint Molecules in Progressive Multifocal Leukoencephalopathy
Progressive multifocal leukoencephalopathy (PML) is a rare viral infection of the central nervous system (CNS) occurring in immunocompromised patients.
- Trial name
- ICIP (NCT04453917)
- Testing
- Collection of blood and urine, Spinal tap, Brain MRI
- Where
- 3 sites in France
- Volunteers
- 22 people
- Sponsor
- University Hospital, Toulouse
Progressive Multifocal Leukoencephalopathy
NT-I7, a Long-Acting Recombinant IL-7 Molecule, as an Immune Reconstitution Strategy for Lymphopenia in Patients With Progressive Multifocal Leukoencephalopathy
Background: Progressive multifocal leukoencephalopathy (PML) is a brain infection. It is caused by a virus. PML can happen in people with a weakened immune system.
- Trial name
- NCT04781309
- Testing
- NT-I7
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Rare Disorders, Undiagnosed Disorders
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
CoRDS, or the Coordination of Rare Diseases at Sanford, is based at Sanford Research in Sioux Falls, South Dakota. It provides researchers with a centralized, international patient registry for all rare diseases.
- Conditions
- Rare Disorders, Undiagnosed Disorders, Disorders of Unknown Prevalence, Cornelia De Lange Syndrome
- Trial name
- CoRDS (NCT01793168)
- Where
- 2 sites in United States, Australia
- Volunteers
- 20,000 people
- Sponsor
- Sanford Health
Multiple Sclerosis
TOPIK Study: A Study to Report Progressive Multifocal Leukoencephalopathy and Other Serious Opportunistic Infections in Natalizumab Treated Participants
The primary objective of the study is to estimate the incidence of progressive multifocal leukoencephalopathy (PML) and serious adverse events (SAEs) of other opportunistic infections (OIs) among all participants taking…
- Trial name
- NCT05236777
- Testing
- Natalizumab
- Where
- 15 sites in Czechia
- Volunteers
- 675 people
- Sponsor
- Biogen
Progressive Multifocal Leukoencephalopathy, PML
Observational Study on Characteristics and Survival Correlates of Progressive Multifocal Leukoencephalopathy (PML) in Italy
The goal of this observational study is to learn about the features of Progressive Multifocal Leukoencephalopathy (PML) at the time of its diagnosis and the factors that may influence the outcome of persons with this disease.
- Trial name
- MI_PML (NCT06594614)
- Where
- Italy
- Volunteers
- 456 people
- Sponsor
- Scientific Institute San Raffaele
Progressive Multifocal Leukoencephalopathy
Tysabri Observational Cohort Study - Multiple Sclerosis (MS) Registries
The primary purpose of this study is to estimate the incidence of progressive multifocal leukoencephalopathy (PML) among patients who switched to Tysabri from disease modifying therapies (DMTs), including newer DMTs (including…
- Trial name
- NCT03399981
- Testing
- Tysabri
- Where
- United States
- Volunteers
- 80,327 people
- Sponsor
- Biogen
Progressive Multifocal Leukoencephalopathy
Pembrolizumab in Progressive Multifocal Leukoencephalopathy (PML) in Immunocompromised Patients Without HIV Infection
This study aims to assess the efficacy and safety of pembrolizumab in immunocompromised patients with progressive multifocal leukoencephalopathy (PML).
- Trial name
- PENALTY (NCT06276504)
- Testing
- Pembrolizumab, 25 mg/ml solution for intravenous (IV) injection
- Where
- 3 sites in France
- Volunteers
- 33 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Progressive Multifocal Leukoencephalopathy
Role of Inflammation in Progressive Multifocal Leukoencephalopathy (PML)
This is a continuation of our previous studies on Progressive Multifocal Leukoencephalopathy (PML). We will focus on the role of inflammation in PML, and define prognostic markers of disease evolution.
- Trial name
- NCT01132053
- Where
- United States
- Volunteers
- 126 people
- Sponsor
- Beth Israel Deaconess Medical Center
Progressive Multifocal Leukoencephalopathy
A Phase 2 Study Evaluating JCPyV-specific T Cell Therapy for PML
This is a randomized, double-blinded, Phase 2 trial in patients with PML due to JCPyV. Patients will receive treatment with a matched virus-specific T-cell product (CE VST01-JC) or placebo, and will then be monitored for response…
- Trial name
- ASCEND-JC (NCT05541549)
- Testing
- CE-VST01-JC
- Volunteers
- 60 people
- Sponsor
- Cellevolve Bio Inc
HIV Infections, Leukoencephalopathy, Progressive Multifocal
Comparison of Anti HIV Drugs Used Alone or in Combination With Cytosine Arabinoside to Treat Progressive Multifocal Leukoencephalopathy (PML) in HIV-Infected Patients
To compare the safety and efficacy of antiretroviral therapy (zidovudine plus either didanosine or dideoxycytidine) versus antiretroviral therapy plus intravenous cytarabine (Ara-C) versus antiretroviral therapy plus intrathecal…
- Trial name
- NCT00001048
- Testing
- Filgrastim, Cytarabine, Zidovudine
- Where
- 9 sites in United States
- Volunteers
- 90 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Leukoencephalopathy, Progressive Multifocal
A Study to Evaluate the Use of Cidofovir (an Experimental Drug) for the Treatment of Progressive Multifocal Leukoencephalopathy (PML) in AIDS Patients
The purpose of this study is to evaluate the safety, tolerance, and overall effectiveness of cidovir to treat PML in AIDS patients.
- Trial name
- NCT00000945
- Testing
- Cidofovir, Probenecid
- Where
- 19 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Multiple Sclerosis
Difference in Efficacy of Natalizumab Versus Fingolimod for the Treatment of Multiple Sclerosis
Under the escalation treatment strategy when a patient displays breakthrough disease parameters under first line therapy, MS physicians are allowed by the EMEA to switch for Natalizumab (NTZ) or fingolimod (FGL).
- Trial name
- BEST-MS (NCT01981161)
- Testing
- biological samples and clinical data
- Where
- 12 sites in France, Germany and 1 more
- Volunteers
- 307 people
- Sponsor
- University Hospital, Toulouse